** Shares of drug developer Xilio Therapeutics XLO.O more than double to $1.37 premarket
** AbbVie ABBV.N and XLO enters into collaboration and option agreement to develop cancer immunotherapies
** Under terms of the deal, XLO to receive $52 million in an upfront payment and will be eligible to receive up to about $2.1 billion in milestone payments
** Deal gives ABBV access to XLO's proprietary tumor-activation technology to develop new immunotherapies
** In the last 12 months, XLO has fallen 7%
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。